Key points at a glance
- Most side effects are GI-related (nausea, vomiting, diarrhoea, constipation) and appear when starting or after a dose increase.
- Serious but uncommon risks include pancreatitis, gallbladder disease, kidney injury from dehydration, severe allergic reactions and, rarely, bowel obstruction symptoms.
- There is a boxed warning about thyroid C‑cell tumours in rodents; tirzepatide is contraindicated in people with personal/family history of medullary thyroid carcinoma or MEN2.
- Hypoglycaemia risk increases if used with insulin or sulfonylureas; prescribers often reduce those doses.
- Tirzepatide slows stomach emptying and can reduce absorption of oral medicines, including the pill—use backup contraception during initiation and after dose changes.
Common tirzepatide side effects
These reactions were frequently reported in SURPASS (type 2 diabetes) and SURMOUNT (weight management) trials. They usually start in the first few weeks, especially after dose escalation, and often settle with time.
- Nausea and vomiting
- Diarrhoea or loose stools
- Constipation
- Abdominal pain, bloating, indigestion, reflux or burping
- Decreased appetite and early fullness
- Headache, dizziness or fatigue
- Injection‑site reactions (mild redness, itch or discomfort)
- Hair shedding was reported in some trials, likely related to rapid weight loss and caloric deficit
Typical timeline: most issues occur after starting or a dose increase, then improve over 2–8 weeks as your body adapts.
Serious risks and warning signs
Call emergency services or seek urgent care if you notice any of the following:
- Possible pancreatitis: severe, persistent upper abdominal pain (may radiate to the back), with or without vomiting.
- Gallbladder problems: right‑upper‑quadrant pain, fever, jaundice, clay‑coloured stools, or severe nausea/vomiting not settling.
- Severe dehydration or kidney issues: very little urine, dizziness, confusion, or fainting, especially with ongoing vomiting/diarrhoea.
- Allergic reaction: rash, hives, swelling of face/lips/tongue, breathing difficulty, or throat tightness.
- Severe GI symptoms: persistent, worsening abdominal pain, inability to pass gas or stools, or repeated uncontrollable vomiting.
- Significant vision changes: especially in people with diabetes (can occur when glucose control improves rapidly).
- Hypoglycaemia (with insulin/sulfonylureas): shakiness, sweating, fast heartbeat, hunger, confusion or fainting.
Who should not take tirzepatide, or needs extra caution
- Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
- Discuss risks carefully if you are pregnant, planning pregnancy or breastfeeding.
- Past pancreatitis or significant gallbladder disease/gallstones.
- Severe gastrointestinal disease (e.g., gastroparesis or severe GERD).
- Advanced kidney disease or history of dehydration.
- Existing or high‑risk diabetic retinopathy.
Interactions and medicine considerations
- Insulin or sulfonylureas: higher risk of low blood sugar. Prescribers often reduce doses when adding tirzepatide.
- Oral contraceptives: delayed gastric emptying can reduce absorption. Use a non‑oral or backup method for 4 weeks after initiation and after each dose increase.
- Other oral medicines: absorption may be delayed. Your prescriber may adjust timing or monitor therapeutic levels where relevant.
- Alcohol: can worsen nausea and increase hypoglycaemia risk in people with diabetes.
Practical tips to reduce side effects
- Follow gradual dose escalation: do not rush increases; allow time for your body to adapt.
- Eat smaller, low‑fat meals: avoid large or high‑fat meals, especially around injection day if they aggravate symptoms.
- Hydrate consistently: sip water or oral rehydration solutions; include electrolytes if you have vomiting/diarrhoea.
- Protein and fibre: favour lean proteins; add gentle fibre for constipation (and a stool softener if advised).
- Limit triggers: greasy, spicy foods, carbonated drinks and alcohol can worsen GI symptoms.
- Set a routine: inject the same day each week; rotate injection sites.
- Ask about anti‑nausea support: if symptoms persist, your prescriber may suggest short‑term medications or dose adjustments.
Australian context and reporting
- Brands: Mounjaro (type 2 diabetes) and Zepbound (weight management) are tirzepatide brands registered with the TGA. Supply and eligibility can vary.
- Report suspected side effects: you can report adverse events to the TGA. This helps improve medicine safety monitoring in Australia.
Related tirzepatide learning paths
Frequently asked questions
How common is nausea on tirzepatide?
Nausea is among the most reported side effects, particularly after starting or raising the dose. It usually improves over several weeks with slower dose escalation and dietary adjustments.
Can tirzepatide cause hair loss?
Hair shedding was reported in some weight management trials. It’s more likely linked to rapid weight loss and reduced caloric/protein intake than to a direct drug effect. Adequate protein and micronutrients may help; discuss with your clinician.
Does tirzepatide increase gallbladder risks?
Yes, incretin‑based therapies are associated with a small increase in gallbladder events. Seek medical care for right‑upper‑abdominal pain, fever, or jaundice.
What if I vomit after my dose?
Hydrate regularly and contact your prescriber if symptoms persist or you cannot keep fluids down. Do not re‑dose unless advised.
Can I use tirzepatide if I have GERD or IBS?
It can worsen GI symptoms in some people. Discuss risks and monitoring with your prescriber before starting.
Is this medical advice?
No. This page is general information. Always follow the advice of your treating clinician and product information approved by the TGA.
Get personalised help with tirzepatide side effects
Describe your symptoms and a clinician or care team member will get back to you. If this is an emergency, call 000.
By submitting, you agree to be contacted about your enquiry. For urgent symptoms, call 000 or attend the nearest emergency department.
Final takeaway
Most tirzepatide side effects are gastrointestinal and improve with time, slower dose increases and simple lifestyle adjustments. Serious events are uncommon but require urgent assessment. If you are unsure how to proceed, ask a clinician.